WST
West Pharmaceutical Services, Inc.
Medical - Instruments & Supplies
Market Cap$23.20B
5Y Perf.+49.0%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
WST vs GTLS vs ATR vs FBIN
Revenue, margins, valuation, and 5-year total return — side by side.
GTLS
Chart Industries, Inc.
Industrial - Machinery
Market Cap$9.93B
5Y Perf.+428.4%
ATR
AptarGroup, Inc.
Medical - Instruments & Supplies
Market Cap$8.05B
5Y Perf.+12.3%
FBIN
Fortune Brands Innovations, Inc.
Construction
Market Cap$4.68B
5Y Perf.-25.0%
WST vs GTLS vs ATR vs FBIN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | WST | GTLS | ATR | FBIN |
|---|---|---|---|---|
| Industry | Medical - Instruments & Supplies | Industrial - Machinery | Medical - Instruments & Supplies | Construction |
| Market Cap | $23.20B | $9.93B | $8.05B | $4.68B |
| Revenue (TTM) | $3.22B | $4.26B | $3.87B | $3.36B |
| Net Income (TTM) | $543M | $40M | $387M | $195M |
| Gross Margin | 36.2% | 32.6% | 21.9% | 45.6% |
| Operating Margin | 20.7% | 8.5% | 13.0% | 10.6% |
| Forward P/E | 37.3x | 16.4x | 22.5x | 11.5x |
| Total Debt | $417M | $3.74B | $1.53B | $2.54B |
| Cash & Equiv. | $791M | $366M | $402M | $264M |
WST vs GTLS vs ATR vs FBIN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
WST
GTLS
ATR
FBIN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| West Pharmaceutical… (WST) | 100 | 149.0 | +49.0% |
| Chart Industries, I… (GTLS) | 100 | 528.4 | +428.4% |
| AptarGroup, Inc. (ATR) | 100 | 112.3 | +12.3% |
| Fortune Brands Inno… (FBIN) | 100 | 75.0 | -25.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: WST vs GTLS vs ATR vs FBIN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: WST leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Fortune Brands Innovations, Inc. is the stronger pick specifically for valuation and capital efficiency and dividend income and shareholder returns. GTLS also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
WST
West Pharmaceutical Services, Inc.
The Growth Play
WST carries the broadest edge in this set and is the clearest fit for growth exposure and sleep-well-at-night.
- Rev growth 6.3%, EPS growth 1.6%, 3Y rev CAGR 2.1%
- Lower volatility, beta 0.92, Low D/E 13.1%, current ratio 3.02x
- 6.3% revenue growth vs FBIN's -3.2%
- 16.9% margin vs GTLS's 0.9%
Best for: growth exposure and sleep-well-at-night
GTLS
Chart Industries, Inc.
The Long-Run Compounder
GTLS is the clearest fit if your priority is long-term compounding.
- 7.7% 10Y total return vs WST's 361.4%
- Beta 0.56 vs FBIN's 1.61
Best for: long-term compounding
ATR
AptarGroup, Inc.
The Income Pick
ATR is the clearest fit if your priority is income & stability and valuation efficiency.
- Dividend streak 33 yrs, beta 0.66, yield 1.4%
- PEG 1.75 vs WST's 4.51
- Beta 0.66, yield 1.4%, current ratio 1.62x
Best for: income & stability and valuation efficiency
FBIN
Fortune Brands Innovations, Inc.
The Value Play
FBIN is the #2 pick in this set and the best alternative if value and dividends is your priority.
- Lower P/E (11.5x vs 16.4x)
- 2.5% yield, 2-year raise streak, vs ATR's 1.4%
Best for: value and dividends
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | WST | 6.3% revenue growth vs FBIN's -3.2% |
| Value | FBIN | Lower P/E (11.5x vs 16.4x) |
| Quality / Margins | WST | 16.9% margin vs GTLS's 0.9% |
| Stability / Safety | GTLS | Beta 0.56 vs FBIN's 1.61 |
| Dividends | FBIN | 2.5% yield, 2-year raise streak, vs ATR's 1.4% |
| Momentum (1Y) | WST | +51.4% vs FBIN's -16.8% |
| Efficiency (ROA) | WST | 13.2% ROA vs GTLS's 0.4%, ROIC 17.5% vs 7.4% |
WST vs GTLS vs ATR vs FBIN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
FY 2025
FY 2025
WST vs GTLS vs ATR vs FBIN — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLWSTLAGGINGATR
Who Leads Where
WST leads in 2 of 6 categories
GTLS leads 2 • FBIN leads 1 • ATR leads 0 • 1 tied
Explore the data ↓ATRAptarGroup, Inc.
0leads
FBINFortune Brands Innova…
1leads
GTLSChart Industries, Inc.
2leads
WSTWest Pharmaceutical S…
2leads
6 Total Categories
CATEGORYLEADERvs GTLSvs FBINMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
WST5/6
Valuation MetricsMultiples, price ratios, and targets
FBIN6/7
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
WST7/9
Total Returns1Y, 3Y, 5Y total returns with dividends
GTLS4/6
Risk & VolatilityBeta, volatility, and downside exposure
GTLS2/2
Analyst OutlookRatings, price targets, and dividends
Tied
—
Income & Cash Flow (Last 12 Months)
WST leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
GTLS and WST operate at a comparable scale, with $4.3B and $3.2B in trailing revenue. WST is the more profitable business, keeping 16.9% of every revenue dollar as net income compared to GTLS's 0.9%. On growth, WST holds the edge at +21.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | WSTWest Pharmaceutic… | GTLSChart Industries,… | ATRAptarGroup, Inc. | FBINFortune Brands In… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $3.2B | $4.3B | $3.9B | $3.4B |
| EBITDAEarnings before interest/tax | $794M | $644M | $801M | $482M |
| Net IncomeAfter-tax profit | $543M | $40M | $387M | $195M |
| Free Cash FlowCash after capex | $458M | $203M | $325M | $420M |
| Gross MarginGross profit ÷ Revenue | +36.2% | +32.6% | +21.9% | +45.6% |
| Operating MarginEBIT ÷ Revenue | +20.7% | +8.5% | +13.0% | +10.6% |
| Net MarginNet income ÷ Revenue | +16.9% | +0.9% | +10.0% | +5.8% |
| FCF MarginFCF ÷ Revenue | +14.2% | +4.8% | +8.4% | +12.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +21.0% | -2.5% | +10.8% | -106.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +56.1% | -36.1% | -4.3% | -2.0% |
WST leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
FBIN leads this category, winning 6 of 7 comparable metrics.
Valuation Metrics
At 15.8x trailing earnings, FBIN trades at a 97% valuation discount to GTLS's 628.5x P/E. Adjusting for growth (PEG ratio), ATR offers better value at 1.65x vs WST's 5.72x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | WSTWest Pharmaceutic… | GTLSChart Industries,… | ATRAptarGroup, Inc. | FBINFortune Brands In… |
|---|---|---|---|---|
| Market CapShares × price | $23.2B | $9.9B | $8.1B | $4.7B |
| Enterprise ValueMkt cap + debt − cash | $22.8B | $13.3B | $9.2B | $7.0B |
| Trailing P/EPrice ÷ TTM EPS | 47.33x | 628.45x | 21.28x | 15.82x |
| Forward P/EPrice ÷ next-FY EPS est. | 37.34x | 16.40x | 22.47x | 11.50x |
| PEG RatioP/E ÷ EPS growth rate | 5.72x | — | 1.65x | 2.77x |
| EV / EBITDAEnterprise value multiple | 30.77x | 14.33x | 11.48x | 10.08x |
| Price / SalesMarket cap ÷ Revenue | 7.55x | 2.33x | 2.13x | 1.05x |
| Price / BookPrice ÷ Book value/share | 7.37x | 2.79x | 3.08x | 1.98x |
| Price / FCFMarket cap ÷ FCF | 49.48x | 48.95x | 26.89x | 12.77x |
FBIN leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
WST leads this category, winning 7 of 9 comparable metrics.
Profitability & Efficiency
ATR delivers a 18.6% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $1 for GTLS. WST carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to GTLS's 1.11x. On the Piotroski fundamental quality scale (0–9), FBIN scores 7/9 vs ATR's 5/9, reflecting strong financial health.
| Metric | WSTWest Pharmaceutic… | GTLSChart Industries,… | ATRAptarGroup, Inc. | FBINFortune Brands In… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +17.9% | +1.2% | +18.6% | +8.3% |
| ROA (TTM)Return on assets | +13.2% | +0.4% | +7.6% | +3.0% |
| ROICReturn on invested capital | +17.5% | +7.4% | +10.7% | +8.1% |
| ROCEReturn on capital employed | +18.4% | +8.6% | +13.8% | +9.9% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 5 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.13x | 1.11x | 0.56x | 1.07x |
| Net DebtTotal debt minus cash | -$375M | $3.4B | $1.1B | $2.3B |
| Cash & Equiv.Liquid assets | $791M | $366M | $402M | $264M |
| Total DebtShort + long-term debt | $417M | $3.7B | $1.5B | $2.5B |
| Interest CoverageEBIT ÷ Interest expense | 3338.00x | 1.08x | 16.19x | 4.72x |
WST leads this category, winning 7 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
GTLS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in GTLS five years ago would be worth $12,951 today (with dividends reinvested), compared to $4,599 for FBIN. Over the past 12 months, WST leads with a +51.4% total return vs FBIN's -16.8%. The 3-year compound annual growth rate (CAGR) favors GTLS at 17.6% vs FBIN's -13.9% — a key indicator of consistent wealth creation.
| Metric | WSTWest Pharmaceutic… | GTLSChart Industries,… | ATRAptarGroup, Inc. | FBINFortune Brands In… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | +16.6% | +0.6% | +2.9% | -22.8% |
| 1-Year ReturnPast 12 months | +51.4% | +37.6% | -16.1% | -16.8% |
| 3-Year ReturnCumulative with dividends | -11.6% | +62.7% | +7.4% | -36.3% |
| 5-Year ReturnCumulative with dividends | -2.4% | +29.5% | -15.3% | -54.0% |
| 10-Year ReturnCumulative with dividends | +361.4% | +772.5% | +83.3% | -2.4% |
| CAGR (3Y)Annualised 3-year return | -4.0% | +17.6% | +2.4% | -13.9% |
GTLS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
GTLS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
GTLS is the less volatile stock with a 0.56 beta — it tends to amplify market swings less than FBIN's 1.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. GTLS currently trades 99.5% from its 52-week high vs FBIN's 60.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | WSTWest Pharmaceutic… | GTLSChart Industries,… | ATRAptarGroup, Inc. | FBINFortune Brands In… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.92x | 0.56x | 0.66x | 1.61x |
| 52-Week HighHighest price in past year | $323.63 | $208.51 | $164.28 | $64.84 |
| 52-Week LowLowest price in past year | $202.79 | $140.50 | $103.23 | $36.07 |
| % of 52W HighCurrent price vs 52-week peak | +99.5% | +99.5% | +76.2% | +60.3% |
| RSI (14)Momentum oscillator 0–100 | 73.2 | 51.2 | 42.8 | 46.8 |
| Avg Volume (50D)Average daily shares traded | 835K | 1.6M | 473K | 2.6M |
GTLS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Evenly matched — ATR and FBIN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: WST as "Buy", GTLS as "Buy", ATR as "Buy", FBIN as "Hold". Consensus price targets imply 53.1% upside for FBIN (target: $60) vs -6.5% for GTLS (target: $194). For income investors, FBIN offers the higher dividend yield at 2.55% vs WST's 0.26%.
| Metric | WSTWest Pharmaceutic… | GTLSChart Industries,… | ATRAptarGroup, Inc. | FBINFortune Brands In… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $315.83 | $193.81 | $169.67 | $59.83 |
| # AnalystsCovering analysts | 14 | 37 | 18 | 27 |
| Dividend YieldAnnual dividend ÷ price | +0.3% | +0.3% | +1.4% | +2.5% |
| Dividend StreakConsecutive years of raises | 25 | 1 | 33 | 2 |
| Dividend / ShareAnnual DPS | $0.84 | $0.60 | $1.81 | $1.00 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | 0.0% | +4.5% | +5.3% |
Evenly matched — ATR and FBIN each lead in 1 of 2 comparable metrics.
Key Takeaway
WST leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). GTLS leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Best OverallWest Pharmaceutical Service… (WST)Leads 2 of 6 categories
Loading custom metrics...
WST vs GTLS vs ATR vs FBIN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is WST or GTLS or ATR or FBIN a better buy right now?
For growth investors, West Pharmaceutical Services, Inc.
(WST) is the stronger pick with 6. 3% revenue growth year-over-year, versus -3. 2% for Fortune Brands Innovations, Inc. (FBIN). Fortune Brands Innovations, Inc. (FBIN) offers the better valuation at 15. 8x trailing P/E (11. 5x forward), making it the more compelling value choice. Analysts rate West Pharmaceutical Services, Inc. (WST) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — WST or GTLS or ATR or FBIN?
On trailing P/E, Fortune Brands Innovations, Inc.
(FBIN) is the cheapest at 15. 8x versus Chart Industries, Inc. at 628. 5x. On forward P/E, Fortune Brands Innovations, Inc. is actually cheaper at 11. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: AptarGroup, Inc. wins at 1. 75x versus West Pharmaceutical Services, Inc. 's 4. 51x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — WST or GTLS or ATR or FBIN?
Over the past 5 years, Chart Industries, Inc.
(GTLS) delivered a total return of +29. 5%, compared to -54. 0% for Fortune Brands Innovations, Inc. (FBIN). Over 10 years, the gap is even starker: GTLS returned +772. 5% versus FBIN's -2. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — WST or GTLS or ATR or FBIN?
By beta (market sensitivity over 5 years), Chart Industries, Inc.
(GTLS) is the lower-risk stock at 0. 56β versus Fortune Brands Innovations, Inc. 's 1. 61β — meaning FBIN is approximately 188% more volatile than GTLS relative to the S&P 500. On balance sheet safety, West Pharmaceutical Services, Inc. (WST) carries a lower debt/equity ratio of 13% versus 111% for Chart Industries, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — WST or GTLS or ATR or FBIN?
By revenue growth (latest reported year), West Pharmaceutical Services, Inc.
(WST) is pulling ahead at 6. 3% versus -3. 2% for Fortune Brands Innovations, Inc. (FBIN). On earnings-per-share growth, the picture is similar: AptarGroup, Inc. grew EPS 6. 3% year-over-year, compared to -92. 0% for Chart Industries, Inc.. Over a 3-year CAGR, GTLS leads at 38. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — WST or GTLS or ATR or FBIN?
West Pharmaceutical Services, Inc.
(WST) is the more profitable company, earning 16. 1% net margin versus 1. 0% for Chart Industries, Inc. — meaning it keeps 16. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WST leads at 20. 1% versus 11. 6% for FBIN. At the gross margin level — before operating expenses — FBIN leads at 44. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is WST or GTLS or ATR or FBIN more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, AptarGroup, Inc. (ATR) is the more undervalued stock at a PEG of 1. 75x versus West Pharmaceutical Services, Inc. 's 4. 51x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Fortune Brands Innovations, Inc. (FBIN) trades at 11. 5x forward P/E versus 37. 3x for West Pharmaceutical Services, Inc. — 25. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for FBIN: 53. 1% to $59. 83.
08Which pays a better dividend — WST or GTLS or ATR or FBIN?
All stocks in this comparison pay dividends.
Fortune Brands Innovations, Inc. (FBIN) offers the highest yield at 2. 5%, versus 0. 3% for West Pharmaceutical Services, Inc. (WST).
09Is WST or GTLS or ATR or FBIN better for a retirement portfolio?
For long-horizon retirement investors, Chart Industries, Inc.
(GTLS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 56), +772. 5% 10Y return). Fortune Brands Innovations, Inc. (FBIN) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (GTLS: +772. 5%, FBIN: -2. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between WST and GTLS and ATR and FBIN?
These companies operate in different sectors (WST (Healthcare) and GTLS (Industrials) and ATR (Healthcare) and FBIN (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: WST is a mid-cap quality compounder stock; GTLS is a small-cap quality compounder stock; ATR is a small-cap quality compounder stock; FBIN is a small-cap deep-value stock. ATR, FBIN pay a dividend while WST, GTLS do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(WST: 21.0% · GTLS: -2.5%)P/E Ratio<
x
(WST: 47.3x · GTLS: 628.5x)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.